Business
Apimeds Pharmaceuticals US closed a December 2025 merger transaction involving MindWave Innovations and Lokahi Therapeutics, leaving Bio Business and Digital Asset segment references in the local bundle.
Apimeds had no revenue, its FY2025 net loss widened to $6.0M, and free cash flow was negative $9.0M.
The read at a glance✓ Audited against SEC data
- Business mix — Biopharma plus digital asset segmentNote
- Revenue — No revenue in the bundleNote
- Profitability — Net loss widened to $6.0MWatch
- Cash — FCF was negative $9.0MWatch
- Balance sheet — Equity rose to $153.3MOK
- Insiders — 0 buys / 0 sellsNote
- Accounting — No forensic screen in bundleNote
Leadership changes
From Apimeds Pharmaceuticals US, Inc.'s own filings, the day they're filed.
- Vin Menon · Chief Executive Officer · appointmenteff. 2026-03-20
- Erick J. Frim · Chief Financial Officer · appointmenteff. 2025-05-30
- Youngjik Cho · Directors · appointment
Latest filings
- 8-K · Company announcement2026-08-21
- 10-Q · Quarterly report2026-08-14
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-07-13
- 10-Q · Quarterly report2026-05-26
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Apimeds Pharmaceuticals US, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.